Foundation Takes No Stand on Treatments

Letters to the Editor

Published August 10, 2011, issue of August 19, 2011.
  • Print
  • Share Share

The Forward’s August 4 article, “Gaucher Disease Patients Get New Hope From Drug,” does not in any way represent the views or opinions of the National Gaucher Foundation. They are, in fact, only those of Cyndi Frank, a patient. Therefore the NGF should not have appeared in that article in any manner.

The NGF does not advocate for any one treatment or pharmaceutical company, as each patient’s needs are different. Only a patient and his or her physician can make an intelligent decision about the proper treatment.

The NGF, a not-for-profit organization, is an unbiased voice for the entire Gaucher community. Our goal is to always present objective and educational information. We worry that the article’s inference that the oral treatment — which has yet to be FDA-approved — is superior to the life-saving drugs that have been and are currently on the market, is misleading. We feel that the article suggests NGF’s endorsement of this treatment. We would like to set the record straight and say that this is not true — it is imperative that we remain unbiased in order to serve the community in the best possible way.

Rhonda P. Buyers

CEO

National Gaucher Foundation

Tucker, Ga.


  • Print
  • Share Share

The Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, the Forward requires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, the Forward reserves the right to remove comments for any reason.






    Would you like to receive updates about new stories?












    We will not share your e-mail address or other personal information.

    Already subscribed? Manage your subscription.